Symbyax

Symbyax is a brand name of fluoxetine/olanzapine, approved by the FDA in the following formulation(s):

SYMBYAX (fluoxetine hydrochloride; olanzapine - capsule; oral)

• 
  Manufacturer: LILLY
  
  Approval date: December 24, 2003
  
  Strength(s): EQ 25MG BASE;EQ 12MG BASE, EQ 25MG BASE;EQ 6MG BASE, EQ 50MG BASE;EQ 12MG BASE, EQ 50MG BASE;EQ 6MG BASE ^[RLD]


• 
  Manufacturer: LILLY
  
  Approval date: April 9, 2007
  
  Strength(s): EQ 25MG BASE;EQ 3MG BASE
  

Has a generic version of Symbyax been approved?

No. There is currently no therapeutically equivalent version of Symbyax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symbyax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  2-methyl-thieno-benzodiazepine
  Patent 5,229,382
  Issued: July 20, 1993
  Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
  Assignee(s): Lilly Industries Limited
  2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
  
  Patent expiration dates:
  
  
  • October 23, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for treating pain
  Patent 5,945,416
  Issued: August 31, 1999
  Inventor(s): Shannon; Harlan E. & Womer; Daniel E.
  Assignee(s): Eli Lilly and Company
  The present invention provides a method for treating pain using a composition comprising olanzapine and Drug Useful in the Treatment of Pain.
  
  Patent expiration dates:
  
  
  • March 24, 2017
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Combination therapy for treatment of refractory depression
  Patent 6,960,577
  Issued: November 1, 2005
  Inventor(s): Tollefson; Gary Dennis
  Assignee(s): Eli Lilly and Company
  Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
  
  Patent expiration dates:
  
  
  • November 1, 2017
    
    ✓ 
    Patent use: SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 19, 2012 - TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
  
  

See also...

• Symbyax Consumer Information (Drugs.com)
• Symbyax Consumer Information (Wolters Kluwer)
• Symbyax Consumer Information (Cerner Multum)
• Symbyax Advanced Consumer Information (Micromedex)
• Olanzapine/Fluoxetine Consumer Information (Wolters Kluwer)
• Fluoxetine and olanzapine Consumer Information (Cerner Multum)
• Olanzapine and fluoxetine Advanced Consumer Information (Micromedex)